Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-248 in Relapsed or Refractory Mantle Cell Lymphoma
NCT07082686Phase 2Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mesutoclax in mantle cell lymphoma (MCL), sponsored by InnoCare Pharma. Started Aug 2025; status: recruiting.
02
Drugs
mesutoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07082686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082686.